Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale

Karen Kaiser*, Jennifer L. Beaumont, Kimberly Webster, Susan E. Yount, Lynne I. Wagner, Timothy M. Kuzel, David Cella

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The Functional Assessment of Cancer Therapy (FACT)-Antiangiogenesis (AntiA) Subscale was developed and validated to enhance treatment decision-making and side effect management for patients receiving anti-angiogenesis therapies. Side effects related to anti-angiogenesis therapies were identified from the literature, clinician input, and patient input. Fifty-nine possible patient expressions of side effects were generated. Patient and clinician ratings of the importance of these expressions led us to develop a 24-item questionnaire with clinical and research potential. To assess the scale's reliability and validity, 167 patients completed the AntiA Subscale, the Functional Assessment of Cancer Therapy-general (FACT-G), the FACT-Kidney Symptom Index (FKSI), the FACIT-Fatigue Subscale, the Global Rating of Change Scale (GRC), and the PROMIS Global Health Scale. Patient responses to the AntiA were analyzed for internal consistency, test-retest reliability, convergent and discriminant validity, and responsiveness to change in clinical status. All tested scales were found to have good internal consistency reliability (Cronbach's alpha 0.70-0.92). Test-retest reliability was also good (0.72-0.88) for total and subscale scores and lower for individual items. The total score, subscale scores, and all single items (except nosebleeds) significantly differentiated between groups defined by level of side effect bother. Evaluation of responsiveness to change in this study was not conclusive, suggesting an area for further research. The AntiA is a reliable and valid measure of side effects from anti-angiogenesis therapy.

Original languageEnglish (US)
Pages (from-to)690-698
Number of pages9
JournalCancer Medicine
Volume4
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Neoplasms
Reproducibility of Results
Therapeutics
Epistaxis
Kidney Neoplasms
Research
Fatigue
Decision Making

Keywords

  • Antiangiogenesis
  • Cancer
  • Patient-reported outcomes
  • Quality of life
  • Side effects

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{8bf9ca13d71f4290a7b5559e2fa85d27,
title = "Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale",
abstract = "The Functional Assessment of Cancer Therapy (FACT)-Antiangiogenesis (AntiA) Subscale was developed and validated to enhance treatment decision-making and side effect management for patients receiving anti-angiogenesis therapies. Side effects related to anti-angiogenesis therapies were identified from the literature, clinician input, and patient input. Fifty-nine possible patient expressions of side effects were generated. Patient and clinician ratings of the importance of these expressions led us to develop a 24-item questionnaire with clinical and research potential. To assess the scale's reliability and validity, 167 patients completed the AntiA Subscale, the Functional Assessment of Cancer Therapy-general (FACT-G), the FACT-Kidney Symptom Index (FKSI), the FACIT-Fatigue Subscale, the Global Rating of Change Scale (GRC), and the PROMIS Global Health Scale. Patient responses to the AntiA were analyzed for internal consistency, test-retest reliability, convergent and discriminant validity, and responsiveness to change in clinical status. All tested scales were found to have good internal consistency reliability (Cronbach's alpha 0.70-0.92). Test-retest reliability was also good (0.72-0.88) for total and subscale scores and lower for individual items. The total score, subscale scores, and all single items (except nosebleeds) significantly differentiated between groups defined by level of side effect bother. Evaluation of responsiveness to change in this study was not conclusive, suggesting an area for further research. The AntiA is a reliable and valid measure of side effects from anti-angiogenesis therapy.",
keywords = "Antiangiogenesis, Cancer, Patient-reported outcomes, Quality of life, Side effects",
author = "Karen Kaiser and Beaumont, {Jennifer L.} and Kimberly Webster and Yount, {Susan E.} and Wagner, {Lynne I.} and Kuzel, {Timothy M.} and David Cella",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/cam4.385",
language = "English (US)",
volume = "4",
pages = "690--698",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale. / Kaiser, Karen; Beaumont, Jennifer L.; Webster, Kimberly; Yount, Susan E.; Wagner, Lynne I.; Kuzel, Timothy M.; Cella, David.

In: Cancer Medicine, Vol. 4, No. 5, 01.05.2015, p. 690-698.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale

AU - Kaiser, Karen

AU - Beaumont, Jennifer L.

AU - Webster, Kimberly

AU - Yount, Susan E.

AU - Wagner, Lynne I.

AU - Kuzel, Timothy M.

AU - Cella, David

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The Functional Assessment of Cancer Therapy (FACT)-Antiangiogenesis (AntiA) Subscale was developed and validated to enhance treatment decision-making and side effect management for patients receiving anti-angiogenesis therapies. Side effects related to anti-angiogenesis therapies were identified from the literature, clinician input, and patient input. Fifty-nine possible patient expressions of side effects were generated. Patient and clinician ratings of the importance of these expressions led us to develop a 24-item questionnaire with clinical and research potential. To assess the scale's reliability and validity, 167 patients completed the AntiA Subscale, the Functional Assessment of Cancer Therapy-general (FACT-G), the FACT-Kidney Symptom Index (FKSI), the FACIT-Fatigue Subscale, the Global Rating of Change Scale (GRC), and the PROMIS Global Health Scale. Patient responses to the AntiA were analyzed for internal consistency, test-retest reliability, convergent and discriminant validity, and responsiveness to change in clinical status. All tested scales were found to have good internal consistency reliability (Cronbach's alpha 0.70-0.92). Test-retest reliability was also good (0.72-0.88) for total and subscale scores and lower for individual items. The total score, subscale scores, and all single items (except nosebleeds) significantly differentiated between groups defined by level of side effect bother. Evaluation of responsiveness to change in this study was not conclusive, suggesting an area for further research. The AntiA is a reliable and valid measure of side effects from anti-angiogenesis therapy.

AB - The Functional Assessment of Cancer Therapy (FACT)-Antiangiogenesis (AntiA) Subscale was developed and validated to enhance treatment decision-making and side effect management for patients receiving anti-angiogenesis therapies. Side effects related to anti-angiogenesis therapies were identified from the literature, clinician input, and patient input. Fifty-nine possible patient expressions of side effects were generated. Patient and clinician ratings of the importance of these expressions led us to develop a 24-item questionnaire with clinical and research potential. To assess the scale's reliability and validity, 167 patients completed the AntiA Subscale, the Functional Assessment of Cancer Therapy-general (FACT-G), the FACT-Kidney Symptom Index (FKSI), the FACIT-Fatigue Subscale, the Global Rating of Change Scale (GRC), and the PROMIS Global Health Scale. Patient responses to the AntiA were analyzed for internal consistency, test-retest reliability, convergent and discriminant validity, and responsiveness to change in clinical status. All tested scales were found to have good internal consistency reliability (Cronbach's alpha 0.70-0.92). Test-retest reliability was also good (0.72-0.88) for total and subscale scores and lower for individual items. The total score, subscale scores, and all single items (except nosebleeds) significantly differentiated between groups defined by level of side effect bother. Evaluation of responsiveness to change in this study was not conclusive, suggesting an area for further research. The AntiA is a reliable and valid measure of side effects from anti-angiogenesis therapy.

KW - Antiangiogenesis

KW - Cancer

KW - Patient-reported outcomes

KW - Quality of life

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=84943590561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943590561&partnerID=8YFLogxK

U2 - 10.1002/cam4.385

DO - 10.1002/cam4.385

M3 - Article

VL - 4

SP - 690

EP - 698

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 5

ER -